The REACT-2 programme measured the prevalence of antibodies to SARS-CoV-2 in a random sample of the adult population in England. From June 2020 to May 2021, over 900,000 people took part, helping us to understand how many people had been infected with the virus and to identify the groups most at risk. It also measured the waning of antibodies over time, and the impact of the vaccination programme on antibody prevalence in the population.

 The findings provided the Government with data on the unequal burden of COVID-19, the likely impact of previous infection and vaccination, informing public health policy.

REACT-2 included a number of sub-studies to evaluate self-antibody testing and ensure that large numbers of people would be able to take part. You can explore these studies below the study video. 

REACT-2: A Nationwide Coronavirus Antibody Study - Imperial College London and Ipsos MORI

REACT-2: A Nationwide Coronavirus Antibody Study

Imperial College London and Ipsos MORI worked together to establish REACT-2, a nationwide at home antibody study with the aim to assess how far COVID-19 infection has already spread. Antibodies are essential in our fight against disease and are a part of the immune system which is able to build an innate response to antigens caused by disease. To test for antibodies a finger prick test is used. As part of REACT-2, nearly 1 million participants were sent test kits.

REACT 2 Sub studies

Contact us

For survey queries only   

Email admin@react.imperial.ac.uk

Please note that when support emails are answered, they will come from the email address support.react@cognitron.co.uk  

Phone: 0207 365 8181 

Support by phone and email will be available from 9am to 5pm, Monday to Friday

For general REACT enquiries 

Email: react.study@imperial.ac.uk

Media

For media or communications enquiries only please contact: Jack Stewart